Result for
Topic: Vaccines and Immunity
June 14, 2021
Safety Immunogenicity and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-Administered With Seasonal Influenza Vaccines
[Pre-print, not peer-reviewed] As part of the Phase 3 randomized trial for the Novavax SARS-CoV-2 vaccine, a sub-study found that co-administration of an influenza vaccine resulted in no change in influenza vaccine immune response, and a slight reduction in antibody responses to the Novavax vaccine. The authors suggest that this could indicate the viability of…
June 11, 2021
Does Reactogenicity after a Second Injection of the BNT162b2 Vaccine Predict Spike IgG Antibody Levels in Healthy Japanese Subjects
[Pre-print, not peer-reviewed] A small study of Japanese healthcare workers (N=67) found that reactogenicity to a second dose of the Pfizer-BioNTech vaccine was not a predictor of subsequent IgG antibody levels. The study controlled for age, sex, and IgG levels after the first dose of vaccine. The prevalence of local and systemic reactogenicity was 2.5-times…
Symptomatic SARS-CoV-2 Infections After Full Schedule BNT162b2 Vaccination in Seropositive Healthcare Workers: A Case Series From a Single Institution
Data from a voluntary surveillance program at a single medical center in Italy revealed that 11 healthcare workers who had been fully vaccinated with the Pfizer-BioNTech vaccine had SARS-CoV-2 detected in nasopharyngeal swabs and 5 of these persons had mild symptoms. The average cycle threshold (Ct) in detected infections was 19 (range 6-26). However, no…
First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland
Compared to those who received one dose of the Pfizer-BioNTech COVID-19 vaccine, receipt of one dose of the Oxford-AstraZeneca vaccine was associated with a higher risk of idiopathic thrombocytopenic purpura (ITP), a blood disorder involving low platelet counts, during 0–27 days after vaccination (adjusted RR = 5.8), with an estimated incidence of 1.13 cases per 100,000…
BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 (first identified in India) and B.1.525 (Eta, first identified in Nigeria). Neutralization of all variants, with the exception of B.1.617.1, was only slightly reduced compared to neutralization of wild-type…
June 10, 2021
Highly-Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
[Pre-print, not peer-reviewed] The Pfizer-BioNTech vaccine only elicited a short-lived mucosal IgA antibody response in a study of 108 vaccinated healthcare workers (HCWs) in Italy without prior infection, with none of the vaccinated HCWs tested for mucosal IgA having a detectable response 2-3 weeks after the second dose. By contrast, the vaccine elicited robust memory…
Neutralizing Antibodies Elicited by the Ad26.COV2.S COVID-19 Vaccine Show Reduced Activity against 501Y.V2 (B.1.351) despite Protection against Severe Disease by This Variant
[Pre-print, not peer-reviewed] Anti-SARS-CoV-2 antibody binding responses among individuals 29 days after vaccination with the single-dose Johnson & Johnson-Janssen vaccine (n=88) were reduced by 1.8-fold against the B.1.351 (Beta) variant compared to the wild-type D614G strain. By contrast, 82% in a subset of 27 individuals showed no neutralizing activity against B.1.351 (Beta) at Day 29…
Association of COVID-19 Vaccination Prioritization and Hospitalization among Older Washingtonians
Prioritization of individuals aged ≥65 years in Washington State for COVID-19 vaccination in January 2021 resulted in an estimated 434 fewer hospitalizations and 122 fewer deaths through March 2021 according to an analysis that compared actual age-specific COVID-19 hospitalization and fatality rates with a synthetic control group generated from a model based on age-specific COVID-19…
Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
[Pre-print, not peer-reviewed] AX290 and AX677 (AXON Neuroscience), second generation monoclonal antibodies developed specifically to target SARS-CoV-2 variants of concern, were experimentally shown to successfully neutralize the wild-type strain, B.1.1.7 (Alpha), and B.1.351 (Beta) in mouse models. Kovacech et al. (June 9, 2021). Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern. Pre-print downloaded Jun 10…
Antibodies Elicited by mRNA-1273 Vaccination Bind More Broadly to the Receptor Binding Domain than Do Those from SARS-CoV-2 Infection
Vaccine-elicited anti-SARS-CoV-2 antibodies in individuals fully vaccinated with the Moderna vaccine in phase 1/2 trials (n=14) were found to target more epitopes within the receptor binding domain (RBD) when compared to individuals with prior infection. Binding of vaccine-elicited antibodies was more broadly distributed across epitopes compared to infection-elicited antibodies within the RBD, which the authors…
Previous page Next page